Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2002

View Archived Issues

Sheffield and Inhale to develop inhaled migraine therapy

Generex completes proof-of-concept study for buccal fentanyl citrate

Potential efficacy of Bay-41-8543 in the treatment of cardiovascular diseases

New antitumor compounds isolated by scientists at Nippon Kayaku

Antiinflammatory and cytoprotective properties of statins

Ad-p53-transduced dendritic cells provide effective immunization and cancer treatment

New data on everolimus presented at the 2002 American Transplant Congress

Y-931, a potential new atypical antipsychotic drug with no cataleptogenic effects

Potential new therapy for stress-related disorders that acts upon CRF1 receptors

AGI-1067 selected as May's Molecule of the Month

CTGF as a therapeutic target in the prevention of nephropathy following kidney transplantation

Antibiotic for drug-resistant infections licensed by PanTherix

Gene-modified autologous tumor cell vaccine tested in patients with metastatic renal cell carcinoma

Glycemic control and improvement in cardiovascular risk factors in diabetes obtained with LY-465608

IND approved for TRAIL-R1 MAb

Identification of serum protein with potential for prostate cancer diagnosis and prognosis

Chiron terminates MIV-150 collaboration with Medivir

Immunex to sell Leukine to Schering AG

Avanir receives CalTIP grant for docosanol-based genital herpes treatment

Fast track designation for oxaliplatin

Antiinflammatory compounds from GSK act by antagonizing the CCR3 receptor

Preparation and use of new NK1 receptor antagonists

New therapies for RSV infections in the BMS pipeline

Novel sulfonamide derivatives identified as inhibitors of JNKs

Integrin receptor antagonists and their use reported by Pharmacia

Immugen presents new anti-HIV agents

Merck claims new PPAR agonists and their use in diabetes and related disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...